Scholar Rock announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer. Dr. Marantz is an accomplished biopharmaceutical executive with over 20 years of industry experience spanning multiple specialties, including neurology, hematology/oncology, and rare diseases. Most recently, Dr. Marantz served as the Executive Vice President and Chief Business Officer at Krystal Biotech.

Previously, she was Senior Vice President and Head of Medical Affairs at Acceleron Pharma, where she was also a member of the R&D leadership team, safety committee, and product development committee that oversaw the research, development, and commercialization strategy. Prior to that, Dr. Marantz was Senior Vice President and Head of Medical Affairs at Alnylam Pharmaceuticals, where she successfully launched ONPATTRO® & GIVLAARI® and built the medical team's global footprint across 19 countries. She also served as Vice President of Global Affairs and the Head of U.S. Medical Affairs and interim Head of Latin America Medical Affairs at Alexion, where she led the complement franchise in hematology, nephrology, and neurology.

Earlier, Dr. Marantz held leadership positions at Biogen, ARIAD and Millennium Pharmaceuticals. Dr. Marantz holds an M.B.A. with a concentration in Finance from the University of California at Berkeley, a Ph.D. in Biochemistry and Molecular Biology from the Medical University of South Carolina, and an M.D. from Tongji Medical College. She currently serves on the board of Arcturus Therapeutics (NASDAQ: ARCT).